Milestones历史沿革 - Nanjing Weili Zhibo Biotechnology Co., Ltd.

Qualifications and honors

2020

2019

2018

2017

Milestones

Company

Company History

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

1998

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2004

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2009

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2013

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2016

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2022

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

1999

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2005

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2008

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2009

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2015

This area can be fully edited and gives you the opportunity to introduce yourself, your website, your products or your services.

2018

Milestones

Return

2014 Nanjing Research & Development Center Established
2015-2016 Angel Round of Financing Completed: Series-Pre-A Financing
2017 LBL-007 Entered Preclinical Research
2018 Completed Series-A Financing

LBL-003 Entered Preclinical Research; Completed Series-A Financing
2019 LBL-007 Clinical Application Approved

LBL-015 Entered Preclinical Research

Signed a Licensing-out Agreement with Pneuma
2020 Completed Series-B Financing

LBL-003 and LBL-015 Obtained Clinical Clearance from U.S. FDA

Signed Collaboration Agreement with Junshi Biosciences Co., Ltd and Xihu Biologicals

2021	Completed Series-C Financing
	LBL-024 Obtained Clinical Clearance from U.S. FDA and China NMPA
	LBL-015 Obtained Clinical Clearance from China NMPA
	LBL-003 Obtained Clinical Clearance from China NMPA
	LBL-019 Obtained Clinical Clearance from U.S. FDA and China NMPA
	Announced Global License and Collaboration Agreement with BeiGene for Anti-LAG-3 Antibody LBL007

2022 LBL-033 IND filed (Implied Approval for Clinical Trial by NMPA)
2023 LBL-033 Phase I Clinical Trial Initiated

LBL-034 First in Human Clinical Trial Application for Relapsed/Refractory Multiple Myeloma Approved by NMPA and FDA

Nanjing Research & Development Center Established
Angel Round of Financing Completed: Series-Pre-A Financing
LBL-007 Entered Preclinical Research
Completed Series-A Financing
———————————————

LBL-003 Entered Preclinical Research
LBL-007 Clinical Application Approved

LBL-015 Entered Preclinical Research

Signed a Licensing-out Agreement with Pneuma
Completed Series-B Financing
———————————————
LBL-003 and LBL-015 Obtained Clinical Clearance from U.S. FDA

Signed Collaboration Agreement with Junshi Biosciences Co., Ltd and Xihu Biologicals
Completed Series-C Financing
———————————
LBL-024 Obtained Clinical Clearance from U.S. FDA and China NMPA
LBL-015 Obtained Clinical Clearance from China NMPA;

LBL-003 Obtained Clinical Clearance from China NMPA

LBL-019 Obtained Clinical Clearance from U.S. FDA and China NMPA Announced Global License and Collaboration Agreement with BeiGene for Anti-LAG-3 Antibody LBL007
LBL-033 IND filed (Implied Approval for Clinical Trial by NMPA)
LBL-033 Phase I Clinical Trial Initiated

LBL-034 First in Human Clinical Trial Application for Relapsed/Refractory Multiple Myeloma Approved by NMPA and FDA

About Us

2018	Completed Series-A Financing
	LBL-003 Entered Preclinical Research; Completed Series-A Financing

2019	LBL-007 Clinical Application Approved
	LBL-015 Entered Preclinical Research
	Signed a Licensing-out Agreement with Pneuma

2020	Completed Series-B Financing
	LBL-003 and LBL-015 Obtained Clinical Clearance from U.S. FDA
	Signed Collaboration Agreement with Junshi Biosciences Co., Ltd and Xihu Biologicals

2023	LBL-033 Phase I Clinical Trial Initiated
	LBL-034 First in Human Clinical Trial Application for Relapsed/Refractory Multiple Myeloma Approved by NMPA and FDA